Top

BY Scott Merville

For decades, combination chemotherapy has been the main treatment for patients with acute myeloid leukemia (AML) – an aggressive cancer of the blood and bone marrow.

“About 40 percent of younger patients survive long term, and for those over 65, survival drops to 10 percent,” says Marina Konopleva, M.D., Ph.D., professor of Leukemia. “There’s been no drug approved for the last 40 years for AML, and outcomes haven...

IACS-1079 drug

BY Scott Merville

New initiatives to improve the treatment of pancreatic cancer have earned two early-career investigators at MD Anderson multi-year support...

BY Scott Merville

MD Anderson Chair of Immunology Jim Allison, Ph.D., whose pivotal work to attack cancer by treating the immune system instead of...

BY Clayton Boldt, Ph.D.

The American Dental Association (ADA) and MD Anderson Cancer Center have announced a joint effort to improve patient outcomes through programs aimed at dental and medical professionals and the public to increase human papillomavirus (HPV) vaccinations and tobacco cessation for oral cancer prevention.

“ADA member dentists promise to put patients first, and as a profession we look for innovative ways to treat...

BY Sarah Watson

Eight MD Anderson researchers have been named 2017 Andrew Sabin Family Fellows. The Andrew Sabin Family Fellowship Program provides $100,000...

BY Ron Gilmore

Guillermina Lozano, Ph.D., chair of Genetics at MD Anderson, is one of 84 new members and 21 foreign associates elected to the National...

BY Bryan Tutt

Cancer patients who have undergone lymph node removal or radiation therapy as part of cancer treatment know all too well the pain and discomfort...

BY Clayton Boldt, Ph.D.

Select breast cancer patients who after undergoing chemotherapy as their first line of treatment show no residual cancer – a state known as...